Two injections, two different problems

Patients often arrive at this comparison expecting to choose the better injection. The more useful question is which problem each injection actually solves — because Cingal and ChondroFiller are not competing answers to the same question.

Cingal is a dual-agent viscosupplement: 88 mg of cross-linked sodium hyaluronate combined with 18 mg of triamcinolone hexacetonide in a single syringe. The hyaluronate restores lubrication to the joint space; the triamcinolone reduces synovial inflammation. Together, they act on the joint environment — the fluid, the lining, the chemical milieu that makes movement painful. Cingal does not alter the cartilage surface itself.

ChondroFiller (Meidrix Biomedicals GmbH) is an acellular type I collagen hydrogel scaffold. Injected under ultrasound guidance into a focal cartilage defect, it self-gels in situ, physically filling the lesion and providing a biological matrix into which the patient's own progenitor cells can migrate. The mechanism is matrix-induced chondrogenesis — the scaffold supports the body's own repair processes rather than delivering cells or growth factors directly.

Neither product is a substitute for the other. Cingal addresses a widespread, inflamed joint; ChondroFiller addresses a discrete structural defect in an otherwise stable one. The distinction is anatomical and pathological, which is why matching the injection to the correct diagnosis matters more than ranking one treatment above the other.

Which patients are suitable for each

Diffuse osteoarthritis and a focal cartilage defect are not simply different points on the same severity scale — the distinction is categorical, and it determines which injection is appropriate.

Cingal suits the more common presentation: widespread joint degeneration accompanied by synovial inflammation. There is no requirement for a discrete structural lesion; the indication is pain, stiffness, and reduced function in a knee where the overall joint environment is compromised. For the majority of patients with symptomatic knee OA, that is precisely the picture that Cingal is designed to address.

ChondroFiller occupies a narrower clinical window. It is appropriate where MRI confirms a focal, contained cartilage defect — typically Grade III or IV — in a joint that is otherwise biomechanically stable. The scaffold relies on the patient's own progenitor cells migrating into the collagen matrix and initiating repair; that process cannot succeed in a joint where the biological environment is too degraded to support it. In generalised diffuse OA, the cellular and biochemical conditions ChondroFiller depends upon are absent, which makes diffuse disease a contraindication rather than merely a relative caution.

Symptom severity alone is not a sufficient basis for choosing ChondroFiller. Clinical pain scores cannot distinguish a focal defect from widespread degeneration — only MRI can. Without imaging confirmation of a contained lesion, ChondroFiller is not clinically justified regardless of symptom burden.

In practice, the two treatments rarely compete for the same patient. An accurate MRI-based assessment tends to resolve the question before any injection decision is reached.

How each injection works in practice

Both treatments are delivered as ultrasound-guided intra-articular injections in an outpatient clinic setting. There are no incisions, no theatre admission, and no general anaesthetic; imaging confirms accurate needle placement throughout.

For Cingal, the procedure is a single intra-articular delivery of the combined hyaluronate–triamcinolone formulation. The corticosteroid component begins reducing inflammation within 24–48 hours, with the hyaluronate supporting joint lubrication in the weeks that follow. Evidence from the pivotal RCT indicates that approach influences outcomes: anteromedial and anterolateral techniques both produced significantly better pain reduction than the lateral midpatellar route at 18 and 26 weeks across all treatment groups — a practical consideration for the administering clinician rather than a fault in the product.

ChondroFiller is placed under ultrasound guidance directly at the defect site. At body temperature it self-polymerises into a hydrogel, physically filling the focal lesion and providing the collagen scaffold through which the patient's own progenitor cells migrate over subsequent months. Patients should expect transient localised swelling in the days after treatment rather than immediate relief; functional gains emerge gradually as the scaffold resorbs and endogenous repair tissue matures. In published cohorts, the bulk of improvement consolidates within the first 12 months.

Onset, durability, and what the evidence shows

The temporal profiles described above translate into meaningfully different evidence records, and understanding what each study design can — and cannot — tell us is important when weighing the two options.

Cingal's pivotal randomised controlled trial demonstrated statistically significant greater pain reduction versus both hyaluronate alone (Monovisc) and saline at up to three weeks post-injection, with WOMAC scores showing sustained improvement through 26 weeks and no serious adverse events recorded. Repeat cycles are spaced at least six months apart. As RCT-level evidence, this gives Cingal one of the stronger evidentiary footings in the viscosupplement category — but it establishes symptom durability rather than structural change.

ChondroFiller's evidence rests on smaller European prospective cohorts rather than a large pivotal RCT. Within those cohorts, IKDC functional scores rise from approximately 48 at baseline to approximately 80 at three years — a mean improvement of around 32 points sustained at 36 months. MRI-based MOCART scores fall consistently between 70 and 87 out of 100 at one year, indicating good-to-excellent structural fill of the repaired defect. Across longer follow-up, 70–85% of patients report meaningful symptom relief at three to five years, with reoperation rates of 3–8%. A 2025 prospective trial by Weninger et al. — which also examined ChondroFiller as an adjunct to autologous mesenchymal stem-cell therapy in 25 Kellgren-Lawrence Grade IV patients — found that the combination produced higher KOOS scores across all subscales at two months compared with stem-cell therapy alone, with MMP-13 used as a cartilage-degradation biomarker.

Neither product has been tested against the other in a head-to-head randomised trial. Any comparative claim rests on cross-study inference rather than controlled data — a limitation that applies equally to both sides of this comparison.

Safety, cost, and access in the UK

Practical planning involves more than efficacy data — safety profile, upfront cost, and funding reality all shape whether a treatment is genuinely accessible.

Safety context

The corticosteroid component in Cingal carries a caveat that applies across all steroid-based injections: repeated high-dose corticosteroid use is associated with cartilage volume loss over time, evidence that has informed clinical caution around standalone steroid cycles. Cingal's formulation addresses this directly by pairing an optimised 18 mg triamcinolone dose with cross-linked hyaluronate, positioning the HA as providing chondroprotective benefit alongside the anti-inflammatory effect. This mitigates rather than removes the concern — Cingal is not intended as an unlimited repeat therapy.

ChondroFiller's post-procedure profile in published cohorts is limited to transient localised swelling in the days following the injection. No serious structural adverse events have been reported across published series, and the overall complaint rate is cited at approximately 0.06%.

Cost and access

The cost difference is considerable. Cingal starts from approximately £1,200 per injection in the UK. ChondroFiller starts from approximately £3,000 for a single-box protocol, rising to £6,000–£11,000 when used alongside a hydrogel or autologous cell therapy in combination approaches.

ChondroFiller is currently excluded from NHS funding and is not reimbursed by major UK private medical insurers, including Bupa and AXA, meaning access is limited to self-funding patients.

Cingal's lower per-injection cost warrants a longer view: patients planning repeat cycles — spaced at a minimum of six-month intervals — should factor cumulative expenditure over several years against ChondroFiller's potentially longer-lasting benefit from a single treatment course.

Getting assessed at London Cartilage Clinic

The choice between these two pathways comes down to a single structural question: is the problem a focal cartilage defect, or diffuse joint degeneration? Where MRI confirms a contained Grade III–IV lesion in an otherwise stable joint, the ChondroFiller collagen scaffold pathway merits serious consideration. Where imaging shows widespread osteoarthritis with synovial inflammation but no discrete focal defect, Cingal is the more appropriate fit. In many presentations, neither answer is obvious from symptoms alone — and in some, a different pathway entirely is indicated.

That determination requires clinical assessment and MRI review, not symptom description. London Cartilage Clinic on Harley Street offers specialist evaluation of focal cartilage pathology, including defect grading, candidacy review for the injectable collagen scaffold pathway, and access to the broader range of injection therapies discussed above. Professor Paul Y. F. Lee leads the cartilage assessment service, where MRI-led defect grading underpins treatment selection.

Patients who have reached this stage of their decision-making can arrange an assessment at londoncartilage.com.